More articles from Interpreting Key Trials

  • Initial Findings of the AASK
    Mahboob Rahman, MD, MS
    Cleveland Clinic Journal of Medicine April 2003, 70 (4) 304-312;

    In a major study, an ACE inhibitor slowed the decline of renal function better than a calcium channel blocker.

  • The ALLHAT Trial
    Donald G. Vidt, MD
    Cleveland Clinic Journal of Medicine March 2003, 70 (3) 263-269;

    Diuretics are unsurpassed in lowering blood pressure, reducing clinical events, tolerability, and low cost.

  • The HIP trial
    Chad L. Deal, MD
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 964-976;

    Patients should be selected for bisphosphonate therapy on the basis of low bone density, not age.

  • Discussing breast cancer and hormone replacement therapy with women
    Pelin Batur, MD, Holly L. Thacker, MD, FACP and Halle C.F. Moore, MD
    Cleveland Clinic Journal of Medicine November 2002, 69 (11) 838-848;

    Although the Women’s Health Initiative showed an increased risk of breast cancer, the absolute risk is very low.

  • The ACUTE Trial
    Craig R. Asher, MD and Allan L. Klein, MD
    Cleveland Clinic Journal of Medicine September 2002, 69 (9) 713-718;

    A TEE-guided approach showed no advantage over conventional management in rates of embolic events, but shortened the anticoagulation course, allowed for earlier cardioversion, and caused fewer bleeding events.

  • GUSTO V: Combination drug treatment of acute myocardial infarction
    Arman T. Askari, MD and A. Michael Lincoff
    Cleveland Clinic Journal of Medicine July 2002, 69 (7) 554-560;

    The combination of abciximab in full doses and reteplase in half doses was not superior to full-dose reteplase alone, but it was “not inferior” either.

  • The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation
    Gregory P. Gerschutz, MD and Deepak L. Bhatt, MD
    Cleveland Clinic Journal of Medicine May 2002, 69 (5) 377-385;

    An important advance, but at the cost of excess bleeding.

  • Statins in acute coronary syndromes: Start them in the hospital
    Monica Acevedo, MD and Dennis L. Sprecher, MD
    Cleveland Clinic Journal of Medicine January 2002, 69 (1) 25-37;

    New data indicate statins should be started as soon as possible in acute coronary syndromes. Current guidelines may need to be changed.

  • GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us
    Derek P. Chew, MBBS and David J. Moliterno, MD
    Cleveland Clinic Journal of Medicine December 2001, 68 (12) 1017-1023;

    Recent trials addressed whether there are clinical differences among these drugs, whether their empiric use is justified in acute coronary syndromes, and whether they might allow for early invasive management in acute coronary syndromes.

  • The Mustt Trial
    Stephen Pavia, MD and Bruce L. Wilkoff, MD
    Cleveland Clinic Journal of Medicine February 2001, 68 (2) 113-129;

    Implantable defibrillators, but not antiarrhythmic drugs reduce the mortality rate in MI survivors at high risk.

Pages